The introduction needs more depth. As a reader I should be able to read it understand what the company does, what issues it faces. Talk more about obesity and diabetes trends.
what do you mean by $1.2 B deficit? Did they report negative earnings of $1.2B in 2006? Or is this a cumulative figure across several years.
Explain what I-class drugs are in layman's terms. The person reading may know nothing of the pharma industry.
Please name and discuss Symylin as well. It doesn't need to be in depth;a sentence or two should be fine. I would also move the part about lack of diversity into this section. This may be in your other chart, but I would include a graph with revenue by product.
Please put numbers on the columns so that it is clear what the revenues and costs are for each year.
Please footnote the graph. In general all footnotes that reference a 10K, should indicate the section and page of the 10-K from which the metric was pulled.
Can you provide any numbers for obesity and diabetes. There are probably some good figures in the obesity and diabetes concept pages or one of the other pharma companies.
Merck should definitely be mentioned.They make Januvia. Januvia, is a direct competitor of Byetta and launched in 2006. Byetta, offers more benefits in the areas of weight loss and also increases GLP-1 production by 10x vs. 4x for Januvia. GLP-1 increases insulin secretion from the pancreas.